Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ViiV’s Visibility Grows And Pressure Mounts For What Comes Next

Executive Summary

GlaxoSmithKline’s HIV-focused business unit is growing leaps and bounds, while the company’s other pharmaceutical sales slump. ViiV CEO Dominique Limet talked in an interview about the increased pressure success brings and how ViiV intends to keep delivering.


Related Content

Is Gilead Vulnerable to ViiV As It Nears End Of HIV R&D Activity?
ICYMI: Biogen, GSK And Roche Slip Pipeline Setbacks Into Earnings Reports
ViiV Poised To Take HIV PrEP Injectable In Late-Stage Trials
When Will Gilead Make Its M&A Move?
GSK Vaccines: Injecting Visibility
Witty Exiting GSK In 2017, Raising Questions About The Firm’s Future
Keeping Track: Imbruvica Snags First-Line CLL Claim; Gilead TAF Strategy Advances
ViiV IPO Plans Ditched By GSK; New Plan Is To Retain Value
Tivicay Launch Returns ViiV To HIV Spotlight And Growth
Glaxo and Pfizer Form HIV Venture, But A Spin-Off Could Be In The Wings


Related Companies